The effect of soluble complement receptor type 1 on hyperacute allograft rejection

Area of Science:

• Transplantation immunology
• Complement biology
• Vascular rejection

Background:

• Antibody-mediated hyperacute rejection is a major barrier in organ transplantation for sensitized recipients.
• The complement cascade plays a critical role in hyperacute rejection.
• Soluble complement receptor type 1 (sCR1) inhibits complement activation.

Purpose of the Study:

• To investigate the efficacy of human recombinant soluble complement receptor type 1 (sCR1) in preventing antibody-mediated hyperacute rejection.
• To assess the impact of sCR1 on complement activity and allograft survival in a rat model.

Main Methods:

• A rat model of hyperacute rejection was established using sensitized Lewis rats receiving ACI cardiac allografts.
• Rats were intravenously administered either sCR1 (3 mg/kg) or phosphate-buffered saline (PBS) prior to reperfusion.
• Hemolytic complement activity and allograft survival were measured; histological examination was performed.

Main Results:

• sCR1 administration significantly reduced hemolytic complement activity by 63% compared to 25% in the PBS group.
• Cardiac allograft survival was prolonged to 32.0 hours in the sCR1 group versus 3.25 hours in the PBS group (P < 0.0001).
• sCR1 therapy prevented the formation of platelet thrombi in allograft coronary vessels.

Conclusions:

• A single dose of sCR1 significantly prolongs cardiac allograft survival in hypersensitized recipients.
• Complement inactivation by sCR1 is a promising strategy for transplantation in sensitized individuals.
• sCR1 demonstrates potential therapeutic value in overcoming antibody-mediated rejection.